Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Amylin

- PMLiVE

NICE in U-turn on Novartis’ Lucentis in diabetic macular oedema

Patient access scheme influences draft recommendation

- PMLiVE

Merck & Co says Januvia follow-up looking good

Diabetes drug shows promise in phase II as once-weekly treatment

JDRF and Lilly take diabetes education to secondary schools

The partnership will use a new resource to teach students about type 1 diabetes

- PMLiVE

AZ share buyback suspension prompts M&A speculation

Analysts query new CEO Pascal Soriot’s intention to preserve cash reserves

- PMLiVE

AZ launches science blog LabTalk

Hopes new blog will build relationships with potential collaborators

Novo Nordisk invests $100m in research in China

Expands existing site in Beijing

Novartis building

CHMP backs trio of Novartis products

Including two diabetes drugs and one for non-cancerous kidney tumours

Diabetes apps present usability problems for older adults

Researchers find a range of potential design problems with smartphone apps

- PMLiVE

AstraZeneca drops Palatin’s obesity drug after trial subject suffers allergic reaction

But collaboration with the US biotech remains in place

- PMLiVE

Lilly launches branded app for emergency diabetes medicine

US-only Lilly Glucagon iPhone and iPad app shows carers how to use the hypoglycaemia treatment

AstraZeneca and BGT shelve experimental sepsis drug

Decision follows CytoFab’s poor mid-stage clinical trial results

GSK pay $3bn to settle drug-marketing case

UK drug-maker pleads guilty for promoting a number of drugs in the US off-label

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links